Takayasu arteritis
Large-vessel vasculitis of young women, the pulse and blood pressure clues, MR angiography as the key test, prednisolone plus a steroid-sparing drug for everyone, and revascularisation only once the disease is quiet.
Tier 2Condition
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- A granulomatous vasculitis of the aorta and its main branches and sometimes the pulmonary arteries. Inflammation thickens the wall, then narrows, occludes or dilates the vessel.
- Young women, usually under 40. Commoner in Japan, Korea, China, India and South-East Asia; rare in Australia, so it is often diagnosed late.
- Think of it in a young person with absent or unequal arm pulses, arm claudication, bruits, unexplained hypertension or a raised CRP with no source.
Loading the rest of the note…
Finished reading?
Sources
- Therapeutic Guidelines: Rheumatology (vasculitis)AU/NZTherapeutic Guidelines Limited (eTG complete), current online version, accessed November 2026
- Pharmaceutical Benefits Scheme: tocilizumab listingsAU/NZAustralian Government Department of Health, Disability and Ageing, online schedule, accessed November 2026
- Mukhtyar CB et al. 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis. Ann Rheum Dis 2026EULAR, 2025 (published July 2026)
- Maz M et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Care Res 2021;73:1071-87American College of Rheumatology, 2021
- Dejaco C et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis 2024;83:741-51EULAR, 2023 update
- Grayson PC et al. 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis 2022;81:1654-60ACR and EULAR, 2022
- Nakaoka Y et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (TAKT). Ann Rheum Dis 2018;77:348-54Annals of the Rheumatic Diseases, 2018
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Personal emails, About story and Australian-style copy